Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This was an early-stage study to test the safety and initial effectiveness of a new two-drug combination for advanced liver cancer. The treatment involved an experimental drug (TQB2223) designed to help the immune system fight cancer, given alongside another immunotherapy drug (p…

This was an early-stage study to find a safe dose and understand how the body processes a new oral drug called TQB3720. It involved 192 men whose prostate cancer had spread and stopped responding to standard hormone treatments. The main goals were to check for side effects and me…

This study tested a new combination of drugs for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The treatment involved an immunotherapy drug (TQB2450) plus standard chemotherapy, with or without another targeted drug (anlotinib), fo…

This early-stage trial tested a new combination of oral and injectable drugs for people with advanced HR-positive, HER2-negative breast cancer that had progressed after hormone therapy. The main goals were to find the safest and most effective dose and to see if the treatment cou…

This study tested an oral capsule called TQB3616 against a placebo in adults with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. The main goal was to see if the drug could delay cancer growth or extend life. The trial was stopped early after enrolling 26 of …

This study tested a combination of two oral drugs, TQ05105 and TQB3909, for adults with moderate-to-high risk myelofibrosis, a serious bone marrow cancer. The main goals were to find a safe dose and see if the treatment could reduce spleen size and ease symptoms. The trial was te…